迷幻藥市場規模、佔有率、成長分析、按來源、按類型、按藥物、按應用、按給藥途徑、按最終用戶、按配銷通路、按地區 - 行業預測，2024-2031 年

2022年全球迷幻藥物市場規模為16億美元，從2023年的17.9億美元成長到2031年的44.7億美元，複合年成長率預計將成長12.1%。

由於人們越來越意識到心理健康治療的重要性以及解決壓力和焦慮等問題的需要，迷幻藥物市場預計將顯著成長。迷幻藥物的出現為精神健康疾病提供了一種創新的治療選擇，儘管面臨一些挑戰，但仍引起了人們的興趣。最近的資料，例如《2022年美國心理健康狀況》報告指出，年輕人嚴重憂鬱症的發生率增加，導致對此類治療的需求進一步增加。政府的合作努力和心理健康意識計劃預計將促進市場擴張。儘管嚴格的監管和潛在的副作用是限制因素，但對該領域的日益接受度以及研發的突破使其成為未來幾年投資和發展的關鍵領域。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 監管環境
• 專利分析
• 案例研究
• 客戶和購買標準分析

迷幻藥市場規模：依來源及複合年成長率（2024-2031）

• 市場概況
• 合成
• 自然的

按類型分類的迷幻藥市場規模和複合年成長率（2024-2031）

• 市場概況
• 同理心來源
• 解離劑
• 其他

迷幻藥市場規模：按藥物和複合年成長率（2024-2031）

• 市場概況
• γ-羥基丁酸 (GHB)
• 氯胺酮
• 裸蓋菇素
• 麥角酸二乙醯胺 (LSD)
• 3,4-甲基安非他命(MDMA)
• 其他

迷幻藥市場規模：按應用和複合年成長率（2024-2031）

• 市場概況
• 發作性睡病
• 抗治療性憂鬱症
• 重度憂鬱症
• 鴉片上癮
• 創傷後壓力症候群（PTSD）
• 其他

迷幻藥市場規模：依給藥途徑及複合年成長率（2024-2031）

• 市場概況
• 口服
• 吸入
• 可注射的

迷幻藥市場規模：按最終用戶和複合年成長率（2024-2031）

• 市場概況
• 醫院
• 專科診所
• 居家護理
• 其他

迷幻藥市場規模：按分銷管道和複合年成長率（2024-2031）

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房

迷幻藥市場規模與複合年成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Pfizer Inc.（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Jazz Pharmaceuticals（Ireland）
• Compass Pathways（UK）
• MindMed（Canada）
• Atai Life Sciences（Germany）
• Cybin Corp.（Canada）
• Field Trip Health（Canada）
• GH Research（Ireland）
• Beckley Psytech（UK）
• Seelos Therapeutics（USA）
• Numinus Wellness Inc.（Canada）
• Delix Therapeutics（USA）
• Mydecine Innovations Group（Canada）
• Revive Therapeutics Ltd.（Canada）
• Entheon Biomedical（Canada）
• Mind Cure Health Inc.（Canada）
• PsyBio Therapeutics（USA）
• Tryp Therapeutics（USA）

結論和建議

Global Psychedelic Drugs Market size was valued at USD 1.6 billion in 2022 and is poised to grow from USD 1.79 billion in 2023 to USD 4.47 billion by 2031, growing at a CAGR of 12.1% during the forecast period (2024-2031).

The psychedelic drug market is poised for significant growth, driven by heightened awareness of mental health treatment's importance and the need to address issues like stress and anxiety. The emergence of psychedelic drugs offers innovative treatment options for mental health disorders, attracting interest despite some challenges. Recent data, such as the 2022 State of Mental Health in America report, highlights a concerning rise in severe depressive episodes among youth, further fueling demand for these therapies. Collaborative government initiatives and mental health awareness programs are expected to bolster market expansion. While stringent regulations and potential side effects pose constraints, the sector's growing acceptance and research breakthroughs position it as a key area for investment and development in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychedelic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychedelic Drugs Market Segmental Analysis

Global Psychedelic Drugs Market is segmented by source, type, drug, application, route of administration, end-user, distribution channel and region. Based on source, the market is segmented into synthetic and natural. Based on type, the market is segmented into empathogens, dissociatives and others. Based on drug, the market is segmented into gamma-hydroxybutyric acid (GHB), ketamine, psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and others. Based on application, the market is segmented into narcolepsy, treatment-resistant depression, major depressive disorder, opiate addiction, post-traumatic stress disorder (PTSD) and others. Based on route of administration, the market is segmented into oral, inhalation and injectable. Based on end-user, the market is segmented into hospitals, specialty clinics, homecare and others. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychedelic Drugs Market

The global psychedelic drugs market is witnessing significant growth driven by the increasing acceptance of these substances for treating depression. Over the past decade, psychedelics have gained recognition for their therapeutic potential in mental health treatment, with researchers actively exploring their efficacy in alleviating symptoms of depression. Ongoing studies and advancements in psychedelic drug development have further enhanced their credibility and acceptance among healthcare professionals and patients alike. As promising results emerge from clinical trials, the popularity and demand for psychedelic therapies are surging, particularly in the United States and various other regions, positioning these factors as key market drivers.

Restraints in the Global Psychedelic Drugs Market

One significant constraint on the Global Psychedelic Drugs market is the elevated cost associated with these substances, which can hinder growth potential. The expensive nature of psychedelic drugs limits accessibility for many patients and consumers, potentially stifling widespread adoption and use. Moreover, the landscape is further complicated by stringent regulations and legal barriers, which can impede market expansion and innovation. These factors combined present challenges that the industry must navigate to achieve sustainable development and broader acceptance within the healthcare sector during the forecasted period. As a result, stakeholders must find solutions to alleviate these concerns for future market success.

Market Trends of the Global Psychedelic Drugs Market

The Global Psychedelic Drugs market is witnessing a notable trend towards the growth of hospital pharmacies, driven by heightened public consciousness surrounding mental health issues and the therapeutic potential of psychedelics. As these substances increasingly require prescriptions from medical professionals, hospital pharmacies are becoming essential distribution channels. This trend is further propelled by a growing body of research supporting the efficacy of psychedelics for specific indications, such as depression, anxiety, and PTSD. Consequently, stakeholders in the healthcare sector are prioritizing the integration of psychedelic therapies, thus fostering a dynamic environment for hospital pharmacies to expand their role in psychiatric treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies
• Customer & Buying Criteria Analysis

Global Psychedelic Drugs Market Size by Source & CAGR (2024-2031)

• Market Overview
• Synthetic
• Natural

Global Psychedelic Drugs Market Size by Type & CAGR (2024-2031)

• Market Overview
• Empathogens
• Dissociatives
• Others

Global Psychedelic Drugs Market Size by Drug & CAGR (2024-2031)

• Market Overview
• Gamma-Hydroxybutyric Acid (GHB)
• Ketamine
• Psilocybin
• Lysergic Acid Diethylamide (LSD)
• 3,4-Methylenedioxymethamphetamine (MDMA)
• Others

Global Psychedelic Drugs Market Size by Application & CAGR (2024-2031)

• Market Overview
• Narcolepsy
• Treatment-Resistant Depression
• Major Depressive Disorder
• Opiate Addiction
• Post-Traumatic Stress Disorder (PTSD)
• Others

Global Psychedelic Drugs Market Size by Route Of Administration & CAGR (2024-2031)

• Market Overview
• Oral
• Inhalation
• Injectable

Global Psychedelic Drugs Market Size by End-User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Psychedelic Drugs Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Psychedelic Drugs Market Size & CAGR (2024-2031)

• North America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • USA
  • Canada
• Europe (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Compass Pathways (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MindMed (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atai Life Sciences (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cybin Corp. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Field Trip Health (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GH Research (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckley Psytech (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seelos Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Numinus Wellness Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Delix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mydecine Innovations Group (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revive Therapeutics Ltd. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Entheon Biomedical (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mind Cure Health Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PsyBio Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tryp Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations